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Transmission and Prevention of Transmission of HIV: Clues
from the Early 21st Century
M. Cohen
UNC Chapel Hill, Chapel Hill, NC, USA
HIV is transmitted by blood and blood products, from HIV
infected mothers to babies (before and during birth, and
through breast milk) and by anal and vaginal intercourse.
The sexual transmission of HIV has lead to the majority
of infections worldwide and this route of transmission has
great variability in efﬁciency (∼1/10-1/1000 transmission
events/sexual exposure). Transmission variability reﬂects
viral concentration in the genital secretions of the infected
host, inﬂammation in the index case or partner, and the sex-
ual acts chosen. HIV prevention depends on complimentary
behavioral and biological strategies. Condoms and male cir-
cumcision reduce the risk of HIV acquisition. No preventive
vaccine has been developed, but a recent trial in Thailand
has suggested potential limited protection from infection,
albeit for a brief period of time. To date all ﬁrst and sec-
ond generation topical vaginal microbicides have failed to
provide reliable and signiﬁcant protection from HIV infec-
tion, but trials with antiretroviral agents are in progress.
The use of oral or topical antiretroviral agents for HIV pre-
vention is considered pre-exposure prophylaxis (PrEP). More
than 20,000 study subjects are enrolled in trials with oral
antiviral agents, especially the combination of tenofovir
and emtricitabine. It is likely that HIV infected patients
receiving antiretroviral therapy are less contagious and a
large randomized controlled trial (HPTN052) has enrolled
more than 1500 HIV discordant couples to address this ques-
tion directly. The enthusiasm for ART as prevention has
led to a ‘‘seek, test and treat strategy’’ now called ‘‘TLC
PLUS’’. . .which requires wider HIV testing (T), linkage (L)
to medical care and delivery of ongoing care (C), PLUS
emphasis on combined behavioral and biological preven-
tion strategies for HIV positive people. Several pilot studies
designed to implement TLC PLUS are underway worldwide.
HIV transmission has been well-studied and prevenntion
strategies are likely to be increasingly successful in the com-
ing years.
doi:10.1016/j.ijid.2010.02.1856
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rowing burden of dengue in Latin America: A public
ealth challenge
. Mendez Galvan
Hospital Infantil de Mexico Federico Gomez, Mexico City,
exico
The evolution of dengue fever and dengue hemorrhagic
ever in the world in the last 50 years shows the lack to
ffective vector control. The re-emergence of dengue fever
nd the new dengue hemorrhagic form in The Americas has
pidemiological, clinical, ecological, political and socioe-
onomic implications. Insufﬁcient political commitment,
nadequate ﬁnancial resources, increased globalization and
rbanization growth have contributed to change the dengue
ituation after 19 Latin American were certiﬁed to have
radicated Aedes aegypti. Difﬁculties begin with diagno-
is (clinical and laboratory), which includes asymptomatic
nfections, undifferentiated febrile illness and differential
iagnosis with other hemorrhagic diseases. Collection of
ppropriate epidemiological data and a true appreciation
f the social and economic impact of dengue are essen-
ial to securing social, political and economic commitment
or dengue control efforts, as well as increased scientiﬁc
nd social awareness. In addition, the estimation of cost-
ffectiveness is necessary in order to deﬁne the optimal
ivision of resources between traditional dengue vector
ontrol and the eventual introduction of dengue vaccines.
urthermore, anticipating the coordination of all the efforts
o facilitate the regulatory requirements and to develop
accination strategies is essential.
oi:10.1016/j.ijid.2010.02.1857
6.002
linical development of tetravalent dengue vaccine for
ndemic areas
. Saville
Sanoﬁ pasteur, Marcy L’Etoile, France
A vaccine to protect against dengue disease is sorely
eeded, particularly for children living in endemic areas
ho are most affected by the disease. The safety and
mmunogenicity of a tetravalent live attenuated dengue vac-
ine containing 5 log10 TCID50 of chimeric yellow fever
YF)/DEN1,2,3,4 viruses (TDV) was tested in children in the
hilippines, where dengue is endemic, and in a region of
exico, where dengue is non-epidemic.
In each of two randomized controlled blind-observer
hase 1 trials (one per country), 126 subjects 2-45 years
ld were enrolled, including 72 2-11 yr olds/study. Sub-
ects were divided into two groups receiving 1) 3 doses of
DV 2) 1 dose of either Stamaril® YF vaccine (Mexico) or
yphim Vi® (Philippines) followed by 2 doses of TVD. Vac-
ines were administered at months 0, 3—4, and 12. Baseline
avivirus serostatus was determined. Vaccine safety and
mmune response were evaluated after each vaccination.
